Literature DB >> 23796270

Two cases of clear cell sarcoma with different clinical and genetic features: cutaneous type with BRAF mutation and subcutaneous type with KIT mutation.

B M Park1, S A Jin, Y D Choi, S H Shin, S T Jung, J B Lee, S C Lee, S J Yun.   

Abstract

Clear cell sarcoma (CCS), also known as malignant melanoma of soft parts, is a rare malignancy constituting approximately 1% of all soft-tissue sarcomas. It occurs predominantly in the lower extremities of young adults, manifesting as a deep, painless, slow-growing mass. CCS is sometimes confused with other types of melanoma because of its melanocytic differentiation. Although BRAF and KIT mutations are well-known melanocytic tumour-promoting mutations frequently found in cutaneous melanoma, they are rare or absent in CCS. We present two cases of CCS with different clinical and genetic features. Both female patients, aged 25 and 20 years, presented with a palpable nodule on a lower extremity. Biopsies of both tumours revealed features diagnostic of CCS. Each tumour cell was positive for S100 protein and HMB-45. However, one patient's tumour was localized to the dermis, with many multinucleated giant cells, whereas the other was located in the deep subcutaneous fat layer near bone. Fluorescence in situ hybridization demonstrated the presence of a characteristic Ewing sarcoma RNA-binding protein (EWSR)1 gene rearrangement in both cases. Reverse-transcription polymerase chain reaction (PCR) and sequencing of the PCR product revealed an EWSR1-activating transcription factor 1 type 1 fusion transcript in both cases. In addition, we detected BRAF mutation in the dermal type and KIT mutation in the subcutaneous type. It is of interest that the BRAF and KIT mutations are known to be very rare in CCS. On the basis of our observations, we suggest that mutation inhibitors may be useful in selected patients with mutated CCS lineages.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23796270     DOI: 10.1111/bjd.12480

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors:  Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Invest New Drugs       Date:  2015-08-20       Impact factor: 3.850

2.  Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report.

Authors:  Marcella Tazzari; Elena Palassini; Barbara Vergani; Antonello Villa; Francesca Rini; Tiziana Negri; Chiara Colombo; Flavio Crippa; Carlo Morosi; Paolo G Casali; Silvana Pilotti; Silvia Stacchiotti; Licia Rivoltini; Chiara Castelli
Journal:  BMC Cancer       Date:  2015-02-14       Impact factor: 4.430

3.  Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

Authors:  Sarina Gouravan; Leonardo A Meza-Zepeda; Ola Myklebost; Eva W Stratford; Else Munthe
Journal:  Int J Mol Sci       Date:  2018-03-23       Impact factor: 5.923

Review 4.  BRAF mutation and its inhibitors in sarcoma treatment.

Authors:  Haotian Liu; Nahar Nazmun; Shafat Hassan; Xinyue Liu; Jilong Yang
Journal:  Cancer Med       Date:  2020-05-31       Impact factor: 4.452

5.  Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma.

Authors:  J Kevin Hicks; Evita Henderson-Jackson; Julia Duggan; David M Joyce; Andrew S Brohl
Journal:  Diagn Pathol       Date:  2018-10-12       Impact factor: 2.644

Review 6.  BRAF gene: From human cancers to developmental syndromes.

Authors:  Muhammad Ramzan Manwar Hussain; Mukhtiar Baig; Hussein Sheik Ali Mohamoud; Zaheer Ulhaq; Daniel C Hoessli; Ghaidaa Siraj Khogeer; Ranem Radwan Al-Sayed; Jumana Yousuf Al-Aama
Journal:  Saudi J Biol Sci       Date:  2014-10-23       Impact factor: 4.219

7.  Primary Clear Cell Sarcoma of the Dermis Mimicking Malignant Melanoma.

Authors:  Ifeyinwa E Obiorah; Pauline Brenholz; Metin Özdemirli
Journal:  Balkan Med J       Date:  2017-10-26       Impact factor: 2.021

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.